Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease

NCT02956954 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Anderson-Fabry Disease

Interventions

DRUG: Enzyme replacement therapy (Agalsidase alpha (Replagal®))
PROCEDURE: Magnetic Resonance Imaging

Sponsor

University Hospital, Rouen